Sangamo scraps public offering ‘after evaluating market conditions’

[cafead]

via Sangamo Therapeutics has withdrawn its public stock offering, according to an SEC filing Friday morning. The cell and gene therapy biotech was hoping to sell a portion of a $500 million shelf offering, announced last week, to push out its cash runway and fund its clinical programs.

article source